CR20200282A - Cápsides variantes de virus adenoasociados y su uso para inhibir la angiogénesis - Google Patents
Cápsides variantes de virus adenoasociados y su uso para inhibir la angiogénesisInfo
- Publication number
- CR20200282A CR20200282A CR20200282A CR20200282A CR20200282A CR 20200282 A CR20200282 A CR 20200282A CR 20200282 A CR20200282 A CR 20200282A CR 20200282 A CR20200282 A CR 20200282A CR 20200282 A CR20200282 A CR 20200282A
- Authority
- CR
- Costa Rica
- Prior art keywords
- aav
- capsid
- virions
- associated virus
- adeno
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Ophthalmology & Optometry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
<p>Se proveen proteínas variantes de la cápside de un virus adenoasociado (AAV) que tienen una o más modificaciones en la secuencia de aminoácidos en relación a una proteína de la cápside de AAV parental, que, cuando están presentes en un virión de AAV, confieren infectividad aumentada de uno o más tipos de células de la retina en comparación con la infectividad de las células de la retina por un virión de AAV que comprende la proteína no modificada de la cápside del AAV parental. También se proveen viriones de AAV recombinantes y composiciones farmacéuticas de los mismos que comprende una proteína variante de la cápside de AAV como se describe en la presente, métodos para elaborar estas proteínas de la cápside y viriones de rAAV, y métodos para usar estas proteínas de la cápside y viriones de rAAV en investigación y en la práctica clínica, por ejemplo en, por ejemplo, la administración de secuencias de ácido nucleico a una o más células de la retina para el tratamiento de trastornos y enfermedades de la retina.</p>
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762590976P | 2017-11-27 | 2017-11-27 | |
US201862664726P | 2018-04-30 | 2018-04-30 | |
PCT/US2018/062478 WO2019104279A1 (en) | 2017-11-27 | 2018-11-26 | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20200282A true CR20200282A (es) | 2021-02-18 |
Family
ID=66631726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20200282A CR20200282A (es) | 2017-11-27 | 2018-11-26 | Cápsides variantes de virus adenoasociados y su uso para inhibir la angiogénesis |
Country Status (21)
Country | Link |
---|---|
US (1) | US11766489B2 (es) |
EP (3) | EP4219695A3 (es) |
JP (3) | JP7184894B2 (es) |
KR (1) | KR20200088853A (es) |
CN (1) | CN111770999A (es) |
AU (2) | AU2018372235B9 (es) |
BR (1) | BR112020010674A2 (es) |
CA (1) | CA3083472A1 (es) |
CL (1) | CL2020001360A1 (es) |
CR (1) | CR20200282A (es) |
DK (1) | DK3717636T3 (es) |
ES (1) | ES2946747T3 (es) |
FI (1) | FI3717636T3 (es) |
IL (1) | IL274712A (es) |
MX (1) | MX2020005451A (es) |
PE (1) | PE20210915A1 (es) |
PH (1) | PH12020550706A1 (es) |
PT (1) | PT3717636T (es) |
SG (1) | SG11202004545XA (es) |
UA (1) | UA127831C2 (es) |
WO (1) | WO2019104279A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
WO2019126329A1 (en) * | 2017-12-19 | 2019-06-27 | Akouos Llc | Aav-mediated delivery of therapeutic antibodies to the inner ear |
CA3100006A1 (en) | 2018-05-11 | 2019-11-14 | Massachusetts Eye And Ear Infirmary | Altering tissue tropism of adeno-associated viruses |
AU2019346447A1 (en) | 2018-09-26 | 2021-04-29 | California Institute Of Technology | Adeno-associated virus compositions for targeted gene therapy |
WO2021050527A1 (en) * | 2019-09-09 | 2021-03-18 | The Regents Of The University Of California | Compositions and methods for making and using multispecific antibodies |
WO2021050614A2 (en) * | 2019-09-09 | 2021-03-18 | Massachusetts Eye And Ear Infirmary | Methods and compositions for modulating the interaction between adeno-associated virus (aav) and the aav receptor (aavr) for altered bio-distribution of aav |
US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
AU2020373326A1 (en) * | 2019-10-31 | 2022-06-02 | Medizinische Hochschule Hannover | AAV vector variants for ocular gene delivery |
WO2022126188A1 (en) * | 2020-12-16 | 2022-06-23 | Children's Medical Research Institute | Aav capsids and vectors |
AU2021401998A1 (en) * | 2020-12-16 | 2023-08-03 | Children's Medical Research Institute | Adeno-associated virus capsids and vectors |
CN113041360A (zh) * | 2021-04-01 | 2021-06-29 | 深圳廷美奥生物技术有限公司 | 一种用于治疗年龄相关性黄斑变性的药物 |
CA3210368A1 (en) * | 2021-04-09 | 2022-10-13 | Shengjiang Liu | Compositions and methods for ocular transgene expression |
EP4326339A2 (en) | 2021-04-20 | 2024-02-28 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Compositions and methods for treating retinal degenerative disorders |
BR112023024375A2 (pt) * | 2021-05-28 | 2024-02-15 | Shanghai Regenelead Therapies Co Ltd | Vírus adeno-associado recombinante tendo capsídeo variante e sua aplicação |
CN113481237A (zh) * | 2021-06-29 | 2021-10-08 | 厦门朔望医药科技有限公司 | 一种预防和治疗新生血管眼部疾病的基因药物 |
AU2022340595A1 (en) * | 2021-09-06 | 2024-04-18 | Huidagene Therapeutics (Singapore) Pte. Ltd. | Treatment of rpe65-associated eye diseases and disorders |
CN114057840B (zh) * | 2021-10-14 | 2022-09-20 | 和元生物技术(上海)股份有限公司 | 包含变异的aav9衣壳蛋白的重组腺相关病毒颗粒 |
AU2022394766A1 (en) * | 2021-11-19 | 2024-06-27 | The University Of Bristol | Materials and methods for treatment of macular degeneration |
CN116444626A (zh) * | 2021-12-28 | 2023-07-18 | 成都弘基生物科技有限公司 | 经过修饰的aav衣壳蛋白及其用途 |
WO2023173086A1 (en) * | 2022-03-11 | 2023-09-14 | Avirmax Biopharma Inc. | Compositions and methods for expressing therapeutics |
CN117180455A (zh) * | 2022-06-07 | 2023-12-08 | 成都弘基生物科技有限公司 | 腺相关病毒药物组合物及其用途 |
WO2024084075A1 (en) | 2022-10-20 | 2024-04-25 | Sparingvision | Compositions and methods for treating retinal degenerative disorders |
CN117304256B (zh) * | 2022-12-08 | 2024-04-16 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
CN117247434B (zh) * | 2023-11-10 | 2024-02-02 | 上海朗昇生物科技有限公司 | 衣壳修饰型病毒载体及其制备和用途 |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US608200A (en) | 1898-08-02 | Toy cannon | ||
AU4645697A (en) | 1996-09-11 | 1998-04-02 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Aav4 vector and uses thereof |
US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
US7323179B2 (en) | 1997-12-19 | 2008-01-29 | Naomi Balaban | Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
CA2745131C (en) | 1998-05-28 | 2016-08-09 | John A. Chiorini | Aav5 vector and uses thereof |
US6984517B1 (en) | 1998-05-28 | 2006-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector and uses thereof |
US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
AU768729B2 (en) | 1998-11-05 | 2004-01-08 | Trustees Of The University Of Pennsylvania, The | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
US6491907B1 (en) | 1998-11-10 | 2002-12-10 | The University Of North Carolina At Chapel Hill | Recombinant parvovirus vectors and method of making |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
ATE293164T1 (de) | 1999-06-08 | 2005-04-15 | Regeneron Pharma | Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften |
JP2003516124A (ja) | 1999-10-15 | 2003-05-13 | ユニバーシティー オブ マサチューセッツ | 標的とした遺伝的干渉の手段としてのrna干渉経路遺伝子 |
AU2001249622B2 (en) | 2000-03-30 | 2007-06-07 | Massachusetts Institute Of Technology | RNA sequence-specific mediators of RNA interference |
WO2001089304A1 (en) | 2000-05-23 | 2001-11-29 | University Of Rochester | Method of producing herpes simplex virus amplicons, resulting amplicons, and their use |
WO2001092513A1 (en) | 2000-05-30 | 2001-12-06 | Johnson & Johnson Research Pty Limited | METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi |
EP1309706A2 (en) | 2000-08-19 | 2003-05-14 | Axordia Limited | Modulation of stem cell differentiation |
WO2002029858A2 (en) | 2000-09-29 | 2002-04-11 | Infineon Technologies North America Corp. | Deep trench etching method to reduce/eliminate formation of black silicon |
KR100879194B1 (ko) | 2000-12-14 | 2009-01-16 | 제넨테크, 인크. | 원핵생물에 의해 제조된 항체 및 이의 용도 |
AU2002248297A1 (en) | 2001-01-05 | 2002-07-16 | Children's Hospital, Inc. | Aav2 vectors and methods |
US7749492B2 (en) | 2001-01-05 | 2010-07-06 | Nationwide Children's Hospital, Inc. | AAV vectors and methods |
US7271002B2 (en) | 2001-11-09 | 2007-09-18 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
ATE520707T1 (de) | 2001-11-13 | 2011-09-15 | Univ Pennsylvania | Verfahren für den nachweis und/oder die identifikation von sequenzen des adeno- assoziierten virus (aav) sowie isolation von dadurch identifizierten, neuen sequenzen |
ES2526341T3 (es) | 2001-12-17 | 2015-01-09 | The Trustees Of The University Of Pennsylvania | Secuencias de serotipo 9 de virus adeno-asociado (AAV), vectores que las contienen, y usos de las mismas |
EP2359869B1 (en) | 2001-12-17 | 2018-12-26 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same and uses therefor |
US20050106558A1 (en) | 2001-12-21 | 2005-05-19 | Luca Perabo | Library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism |
AU2003253595A1 (en) | 2002-04-05 | 2003-11-03 | The Children's Hospital Of Philadelphia | Methods for the production of chimeric adeno-associated virus (aav) vectors, compositions of chimeric aav vectors, and methods of use thereof |
US20060292117A1 (en) | 2002-04-17 | 2006-12-28 | Loiler Scott A | Improved rAAv vectors |
ATE405295T1 (de) | 2002-05-01 | 2008-09-15 | Univ Florida | Verbesserte raav-expressionssysteme für die genetische modifikation spezifischer capsidproteine |
US20040023390A1 (en) | 2002-08-05 | 2004-02-05 | Davidson Beverly L. | SiRNA-mediated gene silencing with viral vectors |
US7220577B2 (en) | 2002-08-28 | 2007-05-22 | University Of Florida Research Foundation, Inc. | Modified AAV |
US7186522B2 (en) | 2003-03-31 | 2007-03-06 | Cytyc Corporation | Papanicolau staining process |
US20060286545A1 (en) | 2003-05-23 | 2006-12-21 | Mount Sinai School Of Medicine Of New York University | Viral vectors with improved properties |
EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
US8071028B2 (en) | 2003-06-12 | 2011-12-06 | Abbott Diabetes Care Inc. | Method and apparatus for providing power management in data communication systems |
ES2862206T3 (es) | 2003-06-19 | 2021-10-07 | Genzyme Corp | Viriones de AAV con inmunorreactividad disminuida y sus usos |
US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
EP2298926A1 (en) | 2003-09-30 | 2011-03-23 | The Trustees of The University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
ES2556710T3 (es) | 2004-09-24 | 2016-01-19 | Novartis Ag | Proteínas capsidiales VP1 modificadas del parvovirus B19 |
NZ555830A (en) | 2004-12-15 | 2009-01-31 | Univ North Carolina | Chimeric vectors |
EP3409296A1 (en) | 2005-04-07 | 2018-12-05 | The Trustees of the University of Pennsylvania | Method of increasing the function of an aav vector |
WO2006119432A2 (en) | 2005-04-29 | 2006-11-09 | The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services | Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes |
SI1945779T1 (sl) | 2005-10-20 | 2013-07-31 | Uniqure Ip B.V. | Izboljĺ ani aav vektorji proizvedeni v celicah insekta |
US7867484B2 (en) | 2006-01-27 | 2011-01-11 | University Of North Carolina At Chapel Hill | Heparin and heparan sulfate binding chimeric vectors |
WO2007120542A2 (en) | 2006-03-30 | 2007-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid library and aav capsid proteins |
US20090317417A1 (en) | 2006-04-28 | 2009-12-24 | The Trustees Of The University Of Pennsylvania | Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof |
US20070274985A1 (en) * | 2006-05-26 | 2007-11-29 | Stefan Dubel | Antibody |
WO2008124015A1 (en) | 2007-04-09 | 2008-10-16 | The Regents Of The University Of California | Methods for purifying adeno-associated virus virions |
HUE030719T2 (en) | 2007-04-09 | 2017-05-29 | Univ Florida | RAAV vector formulations and methods comprising tyrosine-modified capsid proteins for their use |
US20100203083A1 (en) | 2007-05-31 | 2010-08-12 | Medigene Ag | Mutated structural protein of a parvovirus |
EP2012122A1 (en) | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
DK2176283T3 (en) | 2007-07-14 | 2017-02-13 | Univ Iowa Res Found | METHODS AND COMPOSITIONS FOR TREATMENT OF BRAIN DISEASES |
WO2009108274A2 (en) | 2008-02-26 | 2009-09-03 | The University Of North Carolina At Chapel Hill | Methods and compositions for adeno-associated virus (aav) with hi loop mutations |
US8632764B2 (en) | 2008-04-30 | 2014-01-21 | University Of North Carolina At Chapel Hill | Directed evolution and in vivo panning of virus vectors |
WO2009154452A1 (en) | 2008-06-17 | 2009-12-23 | Amsterdam Molecular Therapeutics B.V. | Parvoviral capsid with incorporated Gly-Ala repeat region |
JP2010002479A (ja) | 2008-06-18 | 2010-01-07 | Crossfor:Kk | メガネレンズ用装飾体およびメガネ用装飾体装着具 |
PL3216803T3 (pl) * | 2008-06-25 | 2020-10-19 | Novartis Ag | Stabilne i rozpuszczalne przeciwciała hamujące vegf |
EP2342567A1 (en) | 2008-09-19 | 2011-07-13 | Charité Universitätsmedizin Berlin | Identification and characterisation of recombinant viral gene therapy vectors |
EP2396343B1 (en) | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
WO2010141706A1 (en) | 2009-06-03 | 2010-12-09 | Cedars-Sinai Medical Center | Effective vector platform for gene transfer and gene therapy |
WO2011038187A1 (en) | 2009-09-25 | 2011-03-31 | The Trustees Of The University Of Pennsylvania | Controlled adeno-associated virus (aav) diversification and libraries prepared therefrom |
US8299295B2 (en) | 2009-10-15 | 2012-10-30 | Johnson Matthey Public Limited Company | Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs |
US8263396B2 (en) | 2010-04-01 | 2012-09-11 | Weidong Xiao | Methods and compositions for the production of recombinant virus vectors |
CA3066596A1 (en) | 2010-04-23 | 2011-10-27 | University Of Massachusetts | Cns targeting aav vectors and methods of use thereof |
US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
AU2011256838B2 (en) | 2010-05-17 | 2014-10-09 | Sangamo Therapeutics, Inc. | Novel DNA-binding proteins and uses thereof |
US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
US10415056B2 (en) | 2010-11-10 | 2019-09-17 | Fred Hutchinson Cancer Research Center | Compositions and methods for generating adeno-associated viral vectors with undetectable capsid gene contamination |
WO2012109570A1 (en) | 2011-02-10 | 2012-08-16 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
WO2012112578A2 (en) | 2011-02-14 | 2012-08-23 | The Children's Hospital Of Philadelphia | Improved aav8 vector with enhanced functional activity and methods of use thereof |
PL2675902T3 (pl) | 2011-02-17 | 2019-08-30 | The Trustees Of The University Of Pennsylvania | Kompozycje i sposoby do zmieniania specyficzności względem tkanki i poprawy transferu genu z udziałem aav9 |
KR20220056884A (ko) | 2011-04-22 | 2022-05-06 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 변이체 캡시드를 지니는 아데노-관련 바이러스 및 이의 사용 방법 |
KR101397088B1 (ko) | 2011-06-10 | 2014-05-19 | 강원대학교산학협력단 | 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물 |
WO2012169822A2 (ko) * | 2011-06-10 | 2012-12-13 | 강원대학교산학협력단 | 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물 |
JP6339015B2 (ja) | 2011-08-23 | 2018-06-06 | ロシュ グリクアート アーゲー | 二重特異性t細胞活性化抗原結合分子 |
US9169299B2 (en) | 2011-08-24 | 2015-10-27 | The Board Of Trustees Of The Leleand Stanford Junior University | AAV capsid proteins for nucleic acid transfer |
RU2593950C2 (ru) | 2011-10-21 | 2016-08-10 | Интервет Интернэшнл Б.В. | Рекомбинантный непатогенный mdv-вектор, обеспечивающий полиспецифический иммунитет |
WO2013096955A1 (en) | 2011-12-23 | 2013-06-27 | Case Western Reserve University | Targeted gene modification using hybrid recombinant adeno-associated virus |
US20150111955A1 (en) | 2012-02-17 | 2015-04-23 | The Children's Hospital Of Philadelphia | Aav vector compositions and methods for gene transfer to cells, organs and tissues |
RU2683497C2 (ru) | 2012-04-18 | 2019-03-28 | Дзе Чилдрен'З Хоспитал Оф Филадельфия | Композиция и способы высокоэффективного переноса генов с помощью вариантов капсида aav |
EP2660325A3 (en) | 2012-05-02 | 2014-02-12 | Christian Medical College | AAV vectors and corresponding nucleotide sequences and methods |
WO2013170078A1 (en) | 2012-05-09 | 2013-11-14 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
WO2013174760A1 (en) | 2012-05-25 | 2013-11-28 | Deutsches Krebsforschungszentrum | Optimized aav-vectors for high transduction rates in dendritic cells |
EP2692731A1 (en) | 2012-07-31 | 2014-02-05 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Recombinant Adeno-Associated virus (AAV) vector particles displaying high-affinity ligands for cell-type specific gene delivery |
CN111621507A (zh) | 2012-09-28 | 2020-09-04 | 北卡罗来纳-查佩尔山大学 | 靶向少突胶质细胞的aav载体 |
CN104937100B (zh) | 2012-12-25 | 2020-04-03 | 宝生物工程株式会社 | Aav 变体 |
EP2954051B1 (en) | 2013-02-08 | 2019-03-27 | The Trustees Of The University Of Pennsylvania | Modified aav8 capsid for gene transfer for retinal therapies |
WO2014160092A1 (en) | 2013-03-13 | 2014-10-02 | The Children's Hospital Of Philadelphia | Adeno-associated virus vectors and methods of use thereof |
ES2897508T3 (es) | 2013-05-31 | 2022-03-01 | Univ California | Variantes de virus adenoasociados y métodos de uso de las mismas |
AU2014286996A1 (en) * | 2013-07-12 | 2016-01-07 | Iveric Bio, Inc. | Methods for treating or preventing ophthalmological conditions |
WO2017180936A1 (en) * | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
WO2017186928A1 (en) * | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
WO2017197355A2 (en) * | 2016-05-13 | 2017-11-16 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and methods of use thereof |
SI3471780T1 (sl) | 2016-06-16 | 2021-03-31 | Adverum Biotechnologies, Inc. | Zdravljenje SDM-ja z uporabo različice AAV2 z afliberceptom |
AU2018234918B2 (en) * | 2017-03-17 | 2023-11-02 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression |
RU2770922C2 (ru) | 2017-09-20 | 2022-04-25 | 4Д Молекьюлар Терапьютикс Инк. | Капсиды вариантов аденоассоциированных вирусов и методы их применения |
AU2018350990A1 (en) * | 2017-10-18 | 2020-05-21 | Regenxbio Inc. | Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap |
-
2018
- 2018-11-26 CA CA3083472A patent/CA3083472A1/en active Pending
- 2018-11-26 AU AU2018372235A patent/AU2018372235B9/en active Active
- 2018-11-26 CN CN201880087687.3A patent/CN111770999A/zh active Pending
- 2018-11-26 UA UAA202003841A patent/UA127831C2/uk unknown
- 2018-11-26 MX MX2020005451A patent/MX2020005451A/es unknown
- 2018-11-26 BR BR112020010674-7A patent/BR112020010674A2/pt unknown
- 2018-11-26 EP EP23152950.4A patent/EP4219695A3/en active Pending
- 2018-11-26 ES ES18881166T patent/ES2946747T3/es active Active
- 2018-11-26 EP EP23186524.7A patent/EP4272728A3/en active Pending
- 2018-11-26 DK DK18881166.5T patent/DK3717636T3/da active
- 2018-11-26 FI FIEP18881166.5T patent/FI3717636T3/fi active
- 2018-11-26 JP JP2020528888A patent/JP7184894B2/ja active Active
- 2018-11-26 PE PE2020000575A patent/PE20210915A1/es unknown
- 2018-11-26 SG SG11202004545XA patent/SG11202004545XA/en unknown
- 2018-11-26 KR KR1020207017143A patent/KR20200088853A/ko not_active Application Discontinuation
- 2018-11-26 PT PT188811665T patent/PT3717636T/pt unknown
- 2018-11-26 US US16/765,758 patent/US11766489B2/en active Active
- 2018-11-26 WO PCT/US2018/062478 patent/WO2019104279A1/en unknown
- 2018-11-26 CR CR20200282A patent/CR20200282A/es unknown
- 2018-11-26 EP EP18881166.5A patent/EP3717636B1/en active Active
-
2020
- 2020-05-17 IL IL274712A patent/IL274712A/en unknown
- 2020-05-22 CL CL2020001360A patent/CL2020001360A1/es unknown
- 2020-05-26 PH PH12020550706A patent/PH12020550706A1/en unknown
-
2022
- 2022-05-23 AU AU2022203494A patent/AU2022203494A1/en active Pending
- 2022-06-24 JP JP2022101767A patent/JP2022121534A/ja active Pending
-
2023
- 2023-12-05 JP JP2023205214A patent/JP2024015194A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20200282A (es) | Cápsides variantes de virus adenoasociados y su uso para inhibir la angiogénesis | |
CO2018013255A2 (es) | Cápsides variantes de virus adenoasociados y métodos de uso de estas | |
CL2020000728A1 (es) | Variantes de cápsides de virus adenoasociados y métodos de uso de estas. | |
CL2019002474A1 (es) | Vector clado f de virus adeno-asociado (vaa) y usos relacionados. | |
EA201991911A1 (ru) | Способы и композиции для переноса генов по сосудистой сети | |
MX2022000221A (es) | Viriones de virus adenoasociados con capside variante y metodos para su uso. | |
WO2017058892A3 (en) | Methods and compositions for antibody-evading virus vectors | |
PH12020551096A1 (en) | A modified raav capsid protein for gene therapy | |
CL2019000640A1 (es) | Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso. | |
BR112019002904A2 (pt) | métodos e composições para transferência gênica direcionada | |
AR124119A2 (es) | Partículas virales modificadas y usos de estas | |
CL2022000938A1 (es) | Casete de transferencia de aav | |
CL2021002236A1 (es) | Inserción de vectores de virus adeno-asociados de b-sarcoglicano y el tratamiento de distrofia muscular | |
MX2022000551A (es) | Proteínas de la cápside de aav modificadas para el tratamiento de una enfermedad artrítica. | |
AR121228A1 (es) | Proteínas de la cápside de virus adeno-asociados modificadas para la terapia génica ocular y métodos de uso de las mismas | |
CL2023001650A1 (es) | Tratamiento de la enfermedad de danon | |
MY186651A (en) | Adeno-associated virus variant capsids and methods of use thereof | |
EA202091194A1 (ru) | Вирусные векторы, содержащие области, кодирующие rdh12, и способы лечения дистрофий сетчатки | |
AR119955A1 (es) | Métodos de tratamiento de enfermedades neovasculares oculares utilizando variantes de aav2 que codifican aflibercept | |
TH1801006923A (th) | แคปซิดของไวรัสที่เกี่ยวข้องกับอะดีโนชนิดแวเรียนต์และวิธีการใช้มัน | |
EA202192346A1 (ru) | Доставка -саркогликана с помощью вектора на основе аденоассоциированного вируса и лечение мышечной дистрофии | |
AR120252A1 (es) | Casete de transferencia de aav | |
BR112017017867A2 (pt) | métodos e composições para tratamento de doenças oculares genéticas |